News for MaxCyte, Inc. (MXCL.L)

Stephens has initiated its coverage of MaxCyte (MXCT), assigning an Overweight rating and setting a price target of $6. According to the analyst, the company is

ROCKVILLE, Md., July 09, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ( MXCT), a leading, cell-engineering focused company providing enabling platform technologies

MaxCyte (NASDAQ: MXCT) will announce its Q2 2025 financial results on August 6, 2025, after the U.S. market close. The company will host an earnings

**media[651351,651352]**

We came across a bullish thesis on MaxCyte, Inc. (MXCT) on Substack by OppCost. In this article, we will summarize the bulls’ thesis on MXCT. MaxCyte, Inc. (MXCT)’s share was trading at $2.355 as of May 9th. MaxCyte, Inc. is a commercial-stage cell-engineering company with a strong strategic position in the rapidly growing cell and gene therapy […]

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsEric Abdel - IRMaher Masoud - President and CEODoug...

MaxCyte (MXCT) delivered earnings and revenue surprises of 0% and 7.11%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte (MXCT) to announce Q1 2025 financial results on May 7, 2025, post-U.S. market close. Company to hold an earnings conference call at 4:30 p.m. Ea

**media[591065]**

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday. Shares of Hello Group Inc. MOMO fell sharply during p...

Release Date: March 11, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points MaxCyte Inc (MX

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NMXCT.OQ - MaxCyte IncQ4 2024 MaxCyte Inc Earnings CallMar 11, 2025 / 08:30PM GMT =============

Start Time: 16:30 January 1, 0000 5:12 PM ETMaxCyte, Inc.

**media[538355]**

TG Therapeutics to use MaxCyte's Flow Electroporation® technology and ExPERTâ„¢ platform to support the development and commercialization of azer-cel, its all

**media[534725]**

ROCKVILLE, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ( MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform t

**media[527792]**

**media[513084]**